amphetamine (Mydayis)
Jump to navigation
Jump to search
Indications
- treatment of attention-deficit hyperactivity disorder (ADHD)
Dosage
Adverse effects
- psychosis or mania[5][7][10]
- risk greater than with methylphenidate; absolute risk is low[7]
- 5-fold risk (high dose), 3.5-fold risk (medium dose)[9]
- no risk with methylphenidate[9]
- risk greater than with methylphenidate; absolute risk is low[7]
- delusions
- neurosis[5]
- reversible cerebral vasoconstriction syndrome
- mydriasis
- changes in libido[8]; (methylphenidate associated with priapism)
- insomnia[8]
- tachycardia[8]
- hypertension
- anxiety[8]
- isolated reports of cardiomyopathy associated with chronic amphetamine use[8]
- also see sympathomimetic
- management of toxicity:
- drug adverse effects of ADHD medications
- drug adverse effects of analeptics
- drug adverse effects of psychotropic agents
- drug adverse effects of sympathomimetic(s)
Drug interactions
- avoid beta-blockers
- unopposed alpha-adrenergic activity
- may result in hypertensive crisis
Laboratory
- specimen: serum, plasma (EDTA), urine
- methods:
- interferences:
- urine:
- NaCl causes false negative results
- EIA: labetolol, ranitidine & certain phenothiazines may cause positive results
- EIA, RIA: ephedrine, phenylpropanolamine, benzphetamine, fenfluramine, mephentermine, phenmetrazine, phentermine may cause positive results
- urine:
- amphetamine in specimen
- amphetamines in specimen
Mechanism of action
- enhances release of catecholamines from catecholaminergic neurons
More general terms
More specific terms
Additional terms
Component of
- amphetamine/aspartate/dextroamphetamine
- amphetamine/dextroamphetamine
- Adderall (dextroamphetamine/racemic amphetamine)
References
- ↑ Clinical Guide to Laboratory Tests, 3rd ed. Teitz ed., W.B. Saunders, 1995
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996 pg 220
- ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 15, American College of Physicians, Philadelphia 2009
- ↑ 4.0 4.1 4.2 The Washington Manual of Medical Therapeutics, 33rd edition Foster C et al (eds) Lippincott, Williams & Wilkins, Philadelphia, 2010. pg 985
- ↑ 5.0 5.1 5.2 Beach SR, Kroshinsky D, Kontos N. Case records of the Massachusetts General Hospital. Case 37-2014. A 35-year-old woman with suspected mite infestation. N Engl J Med. 2014 Nov 27;371(22):2115-23 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25427115 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcpc1305989
- ↑ 6.0 6.1 Brooks M FDA Clears Long-Acting ADHD Drug Mydayis. Medscape. June 21, 2017 http://www.medscape.com/viewarticle/881888
- ↑ 7.0 7.1 7.2 Moran LV, Ongur D, Hsu J et al Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. N Engl J Med 2019; 380:1128-1138 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30893533 https://www.nejm.org/doi/full/10.1056/NEJMoa1813751
Cortese S Psychosis during Attention Deficit - Hyperactivity Disorder Treatment with Stimulants. N Engl J Med 2019; 380:1178-1180 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30893541 https://www.nejm.org/doi/full/10.1056/NEJMe1900502 - ↑ 8.0 8.1 8.2 8.3 8.4 8.5 Windle ML Rapid Rx Quiz: Stimulants Medscape.Oct 23, 2022 https://reference.medscape.com/viewarticle/981392
- ↑ 9.0 9.1 9.2 Moran LV, Skinner JP, Shinn AK et al Risk of Incident Psychosis and Mania With Prescription Amphetamines. Am J Psychiatry. 2024 Sep 12:appiajp20230329. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39262211
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedref